

=> d his

(FILE 'HOME' ENTERED AT 09:36:05 ON 03 NOV 2004)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, ...' ENTERED AT 09:36:16 ON 03 NOV 2004

FILE 'MEDLINE' ENTERED AT 09:36:19 ON 03 NOV 2004

L1 9 S EGFR(15W)AUTOPHOS? AND TGF
L2 9 DUP REM L1 (0 DUPLICATES REMOVED)

ANSWER 7 OF 7 MEDLINE on STN

AN 97193876 MEDLINE
DN PubMed ID: 9041461
TI The biologic effects of **C225**, a chimeric monoclonal
antibody to the EGFR, on human **prostate** carcinoma.
AU Prewett M; Rockwell P; Rockwell R F; Giorgio N A; Mendelsohn J; Scher H I;
Goldstein N I
CS Department of Immunology, ImClone Systems Incorporated, New York 10014,
USA.
SO Journal of immunotherapy with emphasis on tumor immunology : official
journal of the Society for Biological Therapy, (1996 Nov) 19 (6) 419-27.
Journal code: 9418950. ISSN: 1067-5582.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199705
ED Entered STN: 19970609
Last Updated on STN: 20000303
Entered Medline: 19970528
AB For **prostate** cancer, a correlation exists between overexpression
of the epidermal growth factor receptor (EGFR) and poor clinical
prognosis. In addition, late-stage metastatic disease is characterized by
a change from a paracrine to an autocrine mode of expression for
TGF-alpha, the ligand for the EGFR. These observations suggest that
activation of the EGFR may be important for the growth of prostatic
carcinoma in situ, and blockade of the receptor-ligand interaction may
offer a means of therapeutic intervention for this disease. We describe
the biologic effects of a chimeric anti-EGFR monoclonal **antibody**
, **C225**, on several human **prostate** tumor cell lines in
culture and the tumor inhibitory properties of the **antibody** for
the treatment of human **prostate** carcinoma xenografts in nude
mice. In vitro analysis of the EGFR from androgen-responsive and
independent prostatic carcinoma cell lines revealed that **C225**
blocked EGF-induced receptor activation and induced internalization of the
receptor. In vivo, a treatment regimen of **C225** alone or
antibody plus doxorubicin significantly inhibited tumor
progression of well-established DU145 and PC-3 xenografts in nude mice.
These results suggest that **C225** may have utility for the
treatment of human **prostate** carcinoma in a clinical setting.

=>